日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

滤泡性淋巴瘤患者长期利妥昔单抗维持治疗:SAKK 35/03随机试验的长期结果

Moccia, Alden A; Taverna, Christian; Schär, Sämi; Vanazzi, Anna; Rondeau, Stéphanie; Hitz, Felicitas; Mingrone, Walter; Pabst, Thomas; Cevreska, Lidija; Del Giglio, Auro; Raats, Johann; Rauch, Daniel; Vorobiof, Daniel A; Lohri, Andreas; Ruegsegger, Céline; Biaggi Rudolf, Christine; Rusterholz, Corinne; Hayoz, Stefanie; Ghielmini, Michele; Zucca, Emanuele

Evaluation of the JAK2V617F Mutational Burden in Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms: A Single-center Experience

费城染色体阴性骨髓增生性肿瘤患者JAK2V617F突变负荷的评估:单中心经验

Popova-Labachevska, M; Panovska-Stavridis, I; Eftimov, A; Kapedanovska, Nestorovska A; Cevreska, L; Ivanovski, M; Ridova, N; Trajkova, S; Dimovski, A J

Analysis of Factors that Influence Hematopoietic Recovery in Autologous Transplanted Patients with Hematopoietic Stem Cells from Peripheral Blood

分析影响自体外周血造血干细胞移植患者造血功能恢复的因素

Grubovic, Rada M; Georgievski, Borce; Cevreska, Lidija; Genadieva-Stavric, Sonja; Grubovic, Milos R

Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03

滤泡性淋巴瘤单药利妥昔单抗诱导治疗后,利妥昔单抗维持治疗最长可达5年:随机对照III期试验SAKK 35/03的结果

Taverna, Christian; Martinelli, Giovanni; Hitz, Felicitas; Mingrone, Walter; Pabst, Thomas; Cevreska, Lidija; Del Giglio, Auro; Vanazzi, Anna; Laszlo, Daniele; Raats, Johann; Rauch, Daniel; Vorobiof, Daniel A; Lohri, Andreas; Biaggi Rudolf, Christine; Rondeau, Stéphanie; Rusterholz, Corinne; Heijnen, Ingmar A F M; Zucca, Emanuele; Ghielmini, Michele